Overnight Digest: Stocks to be kept on radar for February 15
Sensex ended 3 per cent down at 56,405.84 levels whereas Nifty contracted 3.06 per cent settling at 16,842.80 level.
On Monday, the equity markets experienced a bearish day due to increasing tension between the US and Russia over Ukraine which caused a rise in oil prices and led investors to dump risky assets. Sensex ended 3 per cent down at 56,405.84 levels whereas Nifty contracted 3.06 per cent settling at 16,842.80 level.
All the sectoral indices ended in the red with auto, bank, oil & gas, PSU Bank, pharma, FMCG, metal, realty and capital goods indices losing 2-6 per cent. In the broader markets, BSE Midcap and Smallcap indices lost 3-4 per cent.
Watch out for these stocks for Tuesday's trading session:
ONGC - The shares of ONGC hit a fresh 32-month high at Rs 176.40, on gaining 5 per cent on the BSE in Monday’s trading session as oil prices hit their highest in more than seven years on fears of a possible invasion of Ukraine by Russia. The company reported a seven-fold jump in Q3FY22's net profit after higher oil and gas prices offset a reduction in production. In Q3FY22, ONGC’s net profit jumped 597 per cent on a year-on-year basis at Rs 8,764 crore, as against Rs 1,258 crore in the corresponding quarter of the previous fiscal. Revenue in the Q3FY22 was up 67.3 per cent on a YoY basis to Rs 28,474 crore.
FSN E-Commerce Ventures - The shares of FSN E-Commerce Ventures, the parent company of beauty e-tailer Nykaa, have plunged more than 7.5 per cent in Monday's trading session. The share has fallen below its previous low of Rs 1,571.30 touched on January 27, 2022. The stock has dipped 19 per cent in the past one week after the company reported a weak set of numbers for Q3FY22.
Glenmark Pharmaceuticals - The company announced that its subsidiary Glenmark Pharmaceuticals Colombia S.A.S. and Astrazeneca Colombia S.A.S. have entered into an exclusive licensing agreement for the commercialization of AstraZeneca's drug Pulmicort Respules. Under the terms of the agreement, AstraZeneca remains the holder of the registration for Pulmicort Respules and will be responsible for manufacturing and supplying the drug. Glenmark will be responsible for the commercialization of Pulmicort Respules in the Colombian market. The stock has ended at 2.94 per cent lower on Monday.
Upper Circuit Stocks - On Monday, going against the bearish trend, the stocks of Excel Industries and Swelect Energy Systems have locked in 20 per cent and 5 per cent upper circuit respectively. They are likely to be in focus on Tuesday.